Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Founded in 1980, Amgen is a global biotechnology company that develops, manufactures and markets human
therapeutics based on advanced cellular and molecular biology. The company focuses its research and development
efforts on human therapeutics delivered in the form of proteins, monoclonal antibodies and small molecules in the areas
of oncology, haematology, inflammation, neuroscience, bone disorders and metabolic disorders. Amgen has research
facilities in the US, and has clinical development staff in the US, Europe, Canada, Australia and Japan.